Navigation Links
AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
Date:5/7/2008

All amounts are in U.S. dollars

QUEBEC CITY, May 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the first quarter ended March 31, 2008.

First Quarter 2008 Highlights

- Cetrorelix: first patients treated in second efficacy trial of the

Phase 3 program in benign prostatic hyperplasia (BPH);

- AEZS-108: first patients treated in Phase 2 trial in ovarian and

endometrial cancers;

- Miltefosine (Impavido(R)): rights sold to Paladin Labs Inc. (TSX:PLB)

for approximately $8.9 million.

Subsequent to First Quarter End

- Cetrorelix: recruitment of 600 patients completed for first efficacy

trial of the Phase 3 program in BPH;

- Juergen Ernst, AEterna Zentaris Chairman, appointed Interim President

and CEO, replacing David J. Mazzo. Departure of Ellen McDonald, Senior

Vice President, Business Operations and Chief Business Officer;

- Board member Jose P. Dorais appointed to the Corporate Governance,

Nominating and Human Resources Committee, replacing Mr. Juergen Ernst,

the Company's Chairman of the Board and Interim President and CEO, who

had previously stepped down from the committee in connection with his

appointment as Interim President and CEO.

Juergen Ernst, Chairman, Interim President and CEO at AEterna Zentaris commented, "During the quarter, we continued to move forward with our Phase 3 program in BPH with our lead compound cetrorelix, as we completed patient recruitment for our first efficacy trial in North America and started
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... new market research report is ... Whole Exome Sequencing Market ... Preparation, Target Enrichment), by Services ... Synthesis), by Application (Cancer, Monogenic ...
(Date:8/28/2014)... BOSTON , Aug. 28, 2014  Next month, executives ... at three key industry events beginning with Patient-Centered Clinical ... Hotel in Boston , September 4-5. Patient ... , and Aaron Fleishman will share insights on ... how a variety of tactics – from media to mobile ...
(Date:8/28/2014)... Kent, WA (PRWEB) August 28, 2014 ... Synder Filtration’s polymeric membranes to its stable of ... of available molecular weight cut-offs and include membrane filters ... a steady increase in customer demand for our membrane ... a greater variety of flat sheet membranes,” explains Sterlitech ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13BBK Worldwide Leads Sessions at Key September Events 2Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2
... and Two Clinical Candidates Featured -, SOUTH ... a privately held company focused on the discovery,and ... four abstracts have been selected for presentation at ... held in San Diego on,April 12-16, 2008., ...
... Mass., Feb. 12 Mersana, a cancer,therapeutics company, announced ... as Chief Scientific Officer., "We are thrilled that ... said,Julie A. Olson, President and CEO at Mersana. "His ... drug systems are an,ideal match for Mersana. In addition ...
... BOSTON, Feb. 11 PAREXEL International,Corporation (Nasdaq: PRXL ... a 2-for-1 split of its Common Stock, which will ... Holders of PAREXEL,s Common Stock will receive one additional ... held on the record date of,February 22, 2008. The ...
Cached Biology Technology:Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 2Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 3Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D. 2PAREXEL International Announces 2-For-1 Stock Split 2PAREXEL International Announces 2-For-1 Stock Split 3
(Date:8/28/2014)... PAUL (August 28, 2014) Researchers at the University ... facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle ... of potential therapies for FSHD. , The research is ... Cell Reports . , There is no treatment for ... most common type of muscular dystrophy. FSHD is an ...
(Date:8/28/2014)... 2014  Privacy Advocate and Senior Staff Attorney at ... joins the lineup of biometric and mobile commerce experts ... Executive Summit in Tampa, Florida ... speakers include Steven Rahman, Director, Technology and Strategy at Samsung, ... The theme of this year,s event is Mobility at ...
(Date:8/28/2014)... WASHINGTON, Aug. 28, 2014A new method for measuring and ... help doctors and researchers better understand how drug abuse ... surgery and tissue engineering, and lead to better treatment ... by a team of researchers from Stony Brook University ... of Health, was published today in The Optical Society,s ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... flowers and their pollinators have resulted in a ... pollinators such as bees, flies or butterflies to ... evolved intriguing mechanisms and attractants, of which nectar ... discovered that nectars of flowers pollinated by butterflies ...
... in the human gut adaptively shifts more than a ... host's diet changes from sugar to complex carbohydrates. , ... to survive rapidly changing nutrient conditions but also helps ... complex microbial society, according to researchers at Washington University ...
... novel,vaccine that uses immune cells as factories to produce ... breast cancers, say researchers at,The University of Texas M. ... is a protein often present / surexpressed in ... Breast Cancer Research,on Nov. 29, 2004, showed that the ...
Cached Biology News:Highly adaptable genome in gut bacterium key to intestinal health 2Highly adaptable genome in gut bacterium key to intestinal health 3Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 2Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 3
... This system uses the Adept CE 4100 high ... 4200 dual wavelength detector for added ... data processing software and interface unit, CE 4901., ... XP may also be used with Windows 98 ...
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
... EnVision™ G|2 Doublestain System is ... generation visualization kit. The kit is ... the simultaneous detection of two different ... is compatible with suitably diluted rabbit ...
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
Biology Products: